To Compare the safety and efficacy of Vitamin D, with Magnesium in mild to moderate Covid 19 patients

Phase 2

• Conditions: Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

• Registration Number: CTRI/2020/06/026189
• Lead Sponsor: Suraksha Pharma Private Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1.Patients of either sex, 20 to 60 years of age with mild â?? moderate COVID -19 infection , found positive for COVID -19 test by RT_PCR are requiring Clinical management

( symptomatic patients who present with cough, fever, nasal congestion, gastrointestinal symptoms, fatigue, insomnia, ageusia or alternative signs of respiratory infections.)

2.Participants who are willing to provide inform consent and willing to come for schedule follow up visit.

3.Participants who are having normal hematological renal hepatic Parameters

4.Participant not having contra indication to take standard treatment Vitamin D, magnesium

5.Participants tested positive for COVID 19 by nose throat swab using PCR technique

6.Signed informed consent, demonstrating that the subject understands the procedures required for the study and the purpose of the study.

Exclusion Criteria

1.Patient having severe COVID -19 infection

2.Patients presenting severe respiratory and/or multi systemic symptoms compatible with advanced COVID-19 and inter current acute or severe chronic diseases (i.e. active cancer).

3.Participants with hypersensitivity or intolerance or contraindication to the use of standard treatment

4.Participants with known allergy or contraindication to Vitamin D, Magnesium

5.History of having received any investigational drug in the preceding one month.

6.History of taking any kind of formulation or any other form of therapy for COVID 19 prophylaxis .

7.Unwilling to come for regular follow-up for the entire duration of the study.

8. COVID -19 RT-PCR Negative

9.Any condition that, in the opinion of the investigator, does not justify the subjectâ??s inclusion in the study.

10.Participants participating in other clinical study.

11.Participant receiving other immune enhancers.

12.Refusal to sign informed consent form

13.Symptomatic for sever COVID-19 infection needing ICU

14.Atherosclerotic Coronary Artery Disease

Study & Design

• Study Type: Interventional
• Study Design: Not specified